Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.
about
Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development.Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.CYP3A activity: towards dose adaptation to the individual.CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease.Use of microdose phenotyping to individualise dosing of patients.Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects.The pharmacogenetics of medications used in general anesthesia.Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209).Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments.Pediatric microdose and microtracer studies using 14C in Europe.
P2860
Q37701128-34EE5DAA-4580-4498-A2DA-8D17EE5CA739Q38726643-C257AF95-4D4E-4393-AEB1-57620255171FQ38763583-B083E571-461C-45A5-A01E-C1121E48E2DAQ38903289-A7F61B76-1668-4D11-A546-C600AC27ED53Q40996401-2162E67C-76FF-4789-A133-3C88266FA03DQ41328717-F4457B24-1FEA-4352-BC74-59D26B724F0DQ47213395-2C3E89EB-EE81-4153-8C47-A4EA1299C300Q47384439-0BBB1106-14B3-4FA1-8C37-3AE4DEC33CEEQ47425844-1858950F-EEEA-4C67-A91B-1BCE12BBC7D4Q48333024-E8FD2BF3-9522-4DAD-A983-5A8A7DE5FB10Q48333229-FBE267BF-9F87-4BF0-8B1F-A07A329C961BQ49330212-CA9F8802-7E50-4F66-BB2C-BDBFD8FBC536Q53211331-00CC3F6D-4B5E-446A-9E8F-14CC339E0710
P2860
Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Midazolam microdose to determi ...... olic CYP3A activity in humans.
@ast
Midazolam microdose to determi ...... olic CYP3A activity in humans.
@en
type
label
Midazolam microdose to determi ...... olic CYP3A activity in humans.
@ast
Midazolam microdose to determi ...... olic CYP3A activity in humans.
@en
prefLabel
Midazolam microdose to determi ...... olic CYP3A activity in humans.
@ast
Midazolam microdose to determi ...... olic CYP3A activity in humans.
@en
P2860
P50
P356
P1476
Midazolam microdose to determi ...... olic CYP3A activity in humans.
@en
P2093
Alexandra Carls
Franziska Kocheise
P2860
P304
P356
10.1111/BCP.12502
P407
P577
2015-02-01T00:00:00Z